Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement
Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June [_], 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur
How this was made
The 30-second read
Why it matters
Entry into the agreement and the mention of unregistered sales imply new securities issuance that can affect share count, conversion overhang, and near-term trading liquidity.
Market read
Traders should treat this as a fresh financing catalyst for VVOS, with potential dilution/overhang risk until final terms and closing are confirmed.
What to watch
Key missing details (gross proceeds, discount to market, conversion terms, warrant coverage, and closing conditions) determine whether the market reaction is muted or severe; traders should pull the full exhibits and signature pages.
Background
The 8-K references a Securities Purchase Agreement and a Registration Rights Agreement, consistent with a private placement under Securities Act Section 4(a)(2)/Rule 506(b).
Ticker impact
Vivos Therapeutics filed an 8-K for entry into a material definitive securities purchase agreement, indicating a new equity financing.
Near-term volatility possible around deal terms/closing; direction depends on discount size and total proceeds (not provided in the excerpt).
The 8-K confirms a material definitive agreement and unregistered equity issuance, but the excerpt does not include the final pricing, size, or closing details needed to forecast magnitude.
Market effects
Adds to the ongoing pattern of small-cap biotech/healthcare companies using preferred+Warrant structures to raise runway.
Primarily impacts US small-cap biotech sentiment; limited broader regional spillover.
Low—this is company-specific financing with no cross-border deal terms shown in the excerpt.
Counterpoint
If the financing is priced close to market and tied to near-term clinical/commercial milestones, the market may view it as runway-positive rather than purely dilutive.
Key entities
- issuerVivos Therapeutics, Inc.
Company filing the 8-K for entry into a material definitive securities purchase agreement and unregistered equity issuance.
